Author

F. Verheul

Observed names: F Verheul, Francesco E A M Verheul

Observed institutions: The Royal Melbourne Hospital, National Institute for Public Health and the Environment, Groene Hart Ziekenhuis

OpenAlex ID: A5109245967

MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis

2006 · H Butzkueven, J Chapman, et al. · Multiple Sclerosis Journal · 246

The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude

2011 · J Lechner-Scott, B Spencer, et al. · Multiple Sclerosis Journal · 79

Implementing Neonatal Screening for Haemoglobinopathies in the Netherlands

2010 · Marelle J Bouva, Karin Mohrmann, et al. · Journal of Medical Screening · 33

Fluctuations of MS births and UV-light exposure

2012 · F. Verheul, J. Smolders, et al. · Acta Neurologica Scandinavica · 10

Aggressive form of multiple sclerosis can be predicted early after disease onset

2019 · Charles B. Malpas, Ali Manouchehrinia, et al. · Multiple Sclerosis Journal · 5

EXPOSURE TO INTERFERON-β THERAPY IN EARLY PREGNANCY: A LITERATURE REVIEW OF PREGNANCY OUTCOMES IN WOMEN WITH MULTIPLE SCLEROSIS

2012 · S Hughes, T Spelman, et al. · Journal of Neurology Neurosurgery & Psychiatry · 2

Determinants of MS re-activation after discontinuing therapies

2018 · Hafiz Husin, J. Clifford Wallace, et al. · Document Server@UHasselt (UHasselt) · 1

Relapse incidence in women and men throughout the course of multiple sclerosis: An MSBase cohort study

2013 · Tomáš Kalinčík, V. Vivek, et al. · Murdoch University Research Portal · 1

Modifiers of the effectiveness of MS immunotherapies

2019 · Tomáš Kalinčík, Charles B. Malpas, et al. · Multiple Sclerosis Journal

Early clinical predictors of severe MS

2018 · Charles B. Malpas, Samira Sharmin, et al. · Multiple Sclerosis Journal

Pregnancy protects against long-term disability accrual in relapsing-remitting MS

2016 · V. Jokubaitis, Tomáš Kalinčík, et al. · Multiple Sclerosis Journal

Individual response to disease modifying therapies: a global observational cohort study

2016 · Tomáš Kalinčík, Lukáš Sobíšek, et al. · Multiple Sclerosis Journal

Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a

2016 · Tomáš Kalinčík, John W. Brown, et al. · Multiple Sclerosis Journal

Comparison of MS outcomes after Switching to Natalizumab versus staying on Interferon-beta or glatiramer

2016 · Timothy Spelman, Guillermo Izquierdo, et al. · Multiple Sclerosis Journal

10-year progression predictors after first treatment initiation in a relapsing-remitting MS cohort

2015 · V. Jokubaitis, Tim Spelman, et al. · Multiple Sclerosis Journal

Evaluation of common criteria of progression of disability in a large observational cohort

2014 · Tomáš Kalinčík, Vilija Jokubaitis, et al. · Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)

P622: Lumbar spinal stenosis: an underestimated diagnosis?

2014 · L. Teunissen, F. Verheul, et al. · Clinical Neurophysiology

Comparative efficacy of switch to natalizumab or fingolimod in active relapsing-remitting multiple sclerosis

2014 · Tomáš Kalinčík, Dana Horáková, et al.

After a relapse, patients who switch to natalizumab have better outcomes than those who switch between platform therapies

2014 · Maria Trojano, Timothy Spelman, et al. · European Journal of Neurology

Seasonal variation of relapse rate in MS is latitude-dependent.

2014 · Tim Spelman, Orla Gray, et al. · Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)

Symptomatology of multiple sclerosis relapses varies in relation to demographic and clinical factors

2013 · Tomáš Kalinčík, Katherine Buzzard, et al. · Murdoch University Research Portal

Works count: 21

Citation count: 377

H-index: 5

I10-index: 4